Page 25 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19

upregulates synthesis of α-synuclein in these dendritic cells, increasing the risk of prion formation.
Prions that accumulate in the cytoplasm are packaged up into lipid bodies that are released as
exosomes (Liu et al., 2017). These exosomes eventually travel to the brain, causing disease.

2. Vaccine Shedding

There has been considerable chatter on the Internet about the possibility of vaccinated people
causing disease in unvaccinated people in close proximity. While this may seem hard to believe,
there is a plausible process by which it could occur through the release of exosomes from dendritic
cells in the spleen containing misfolded spike proteins, in complex with other prion reconformed
proteins. These exosomes can travel to distant places. It is not impossible to imagine that they are
being released from the lungs and inhaled by a nearby person. Extracellular vesicles, including
exosomes, have been detected in sputum, mucus, epithelial lining fluid, and bronchoalveolar lavage
fluid in association with respiratory diseases (Lucchetti et al., 2021).
A Phase 1/2/3 study undertaken by BioNTech on the Pfizer mRNA vaccine implied in their study
protocol that they anticipated the possibility of secondary exposure to the vaccine (BioNTech,
2020). The protocol included the requirement that “exposure during pregnancy” should be reported
by the study participants. They then gave examples of “environmental exposure during pregnancy”
which included exposure “to the study intervention by inhalation or skin contact.” They even
suggested two levels of indirect exposure: “A male family member or healthcare provider who has
been exposed to the study intervention by inhalation or skin contact then exposes his female partner
prior to or around the time of conception.”

Emergence of Novel Variants of SARS-CoV-2

An interesting hypothesis has been proposed in a paper published in Nature, which described a case
of serious COVID-19 disease in a cancer patient who was taking immune-suppressing cancer
chemotherapy drugs (Kemp et al., 2021). The patient survived for 101 days after admission to the
hospital, finally succumbing in the battle against the virus. The patient constantly shed viruses over
the entire 101 days, and therefore he was moved to a negative-pressure high air-change infectious
disease isolation room, to prevent contagious spread.

During the course of the hospital stay, the patient was treated with Remdesivir and subsequently
with two rounds of antibody-containing plasma taken from individuals who had recovered from
COVID-19 (convalescent plasma). It was only after the plasma treatments that the virus began to
rapidly mutate, and a dominant new strain eventually emerged, verified from samples taken from the
nose and throat of the patient. An immune-compromised patient offers little support from cytotoxic
T cells to clear the virus.

An in vitro experiment demonstrated that this mutant strain had reduced sensitivity to multiple units
of convalescent plasma taken from several recovered patients. The authors proposed that the
administered antibodies had actually accelerated the mutation rate in the virus, because the patient
was unable to fully clear the virus due to their weak immune response. This allowed a “survival of
the fittest” program to set in, ultimately populating the patient’s body with a novel antibody-resistant
strain. Prolonged viral replication in this patient led to “viral immune escape,” and similar resistant

International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 413